View Financial HealthArterra Bioscience 배당 및 자사주 매입배당 기준 점검 3/6Arterra Bioscience 수익으로 충분히 충당되는 현재 수익률 4.51% 보유한 배당금 지급 회사입니다.핵심 정보4.5%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향65%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).분석 기사 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...분석 기사 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...모든 업데이트 보기Recent updates분석 기사 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).New Risk • Apr 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Minor Risks Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.4m market cap, or US$23.9m).Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.분석 기사 • Mar 28Here's Why We Think Arterra Bioscience (BIT:ARBS) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...공시 • Jan 21Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million.Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million on January 20, 2026. A cash consideration valued at €3.2 per share will be paid by Smart Capital S.p.A. Following the transaction, which took place outside the market, Smart Capital will hold 799,500 shares, thus increasing its stake from 5.00% to 12.01% of Arterra's share capital. Smart Capital S.p.A. (BIT:SMCAP) completed the acquisition of an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) on January 20, 2026.New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.8m market cap, or US$24.2m).Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €3.32, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total returns to shareholders of 114% over the past three years.New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (217% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€17.0m market cap, or US$19.8m).New Risk • May 22New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 289% Dividend yield: 5.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (289% cash payout ratio). Market cap is less than US$100m (€15.6m market cap, or US$17.6m).Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.6m revenue, or US$4.2m). Market cap is less than US$100m (€14.9m market cap, or US$17.0m).분석 기사 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...Buy Or Sell Opportunity • Apr 07Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €2.16. The fair value is estimated to be €1.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only.공시 • Apr 07Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Location: via benedetto brin n 69 Italy분석 기사 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...Declared Dividend • Mar 31Dividend increased to €0.13Dividend of €0.13 is 30% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 6.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 31% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.공시 • Mar 30Arterra Bioscience S.p.A. announces Annual dividend, payable on May 07, 2025Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1300 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.Upcoming Dividend • Apr 29Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Trailing yield: 5.2%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.8%).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (€13.0m market cap, or US$13.8m).분석 기사 • Feb 13Arterra Bioscience S.p.A.'s (BIT:ARBS) P/E Is On The MarkThere wouldn't be many who think Arterra Bioscience S.p.A.'s ( BIT:ARBS ) price-to-earnings (or "P/E") ratio of 12.6x...Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.64, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 44% over the past three years.Buying Opportunity • Sep 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €2.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only.분석 기사 • Aug 03A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ARBS)Key Insights The projected fair value for Arterra Bioscience is €1.90 based on 2 Stage Free Cash Flow to Equity Arterra...Upcoming Dividend • May 01Upcoming dividend of €0.10 per share at 4.0% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 4.0%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.4%).분석 기사 • Jan 09A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ABS)Key Insights Arterra Bioscience's estimated fair value is €2.3 based on 2 Stage Free Cash Flow to Equity Current share...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Counselor Lucio Annunziato was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €2.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past year.Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €2.21m (up 40% from 1H 2020). Net income: €390.6k (up 13% from 1H 2020). Profit margin: 18% (down from 22% in 1H 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 13Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €4.17m (up 19% from FY 2019). Net income: €1.11m (up 29% from FY 2019). Profit margin: 27% (up from 24% in FY 2019). The increase in margin was driven by higher revenue.분석 기사 • May 27Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 23% share price gain to €4.08, the stock trades at a trailing P/E ratio of 46.8x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to €3.41, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total return to shareholders over the past year is a loss of 7.8%.Is New 90 Day High Low • Jan 08New 90-day high: €3.41The company is up 15% from its price of €2.96 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €2.80The company is down 2.0% from its price of €2.87 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, ARBS 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: ARBS 의 배당금 지급이 증가했지만 회사는 4 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Arterra Bioscience 배당 수익률 vs 시장ARBS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARBS)4.5%시장 하위 25% (IT)1.6%시장 상위 25% (IT)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (ARBS) (최대 3년)n/a주목할만한 배당금: ARBS 의 배당금( 4.51% )은 Italian 시장에서 배당금 지급자의 하위 25%( 1.65% )보다 높습니다.고배당: ARBS 의 배당금( 4.51% )은 Italian 시장에서 배당금 지급자의 상위 25%( 4.53% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 64.8% )을 통해 ARBS 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 56.1% )로 ARBS 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 02:51종가2026/05/25 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Arterra Bioscience S.p.A.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Valentina RomitelliValueTrack
Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).
Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).
분석 기사 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...
분석 기사 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...
분석 기사 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...
Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).
New Risk • Apr 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Minor Risks Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.4m market cap, or US$23.9m).
Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
분석 기사 • Mar 28Here's Why We Think Arterra Bioscience (BIT:ARBS) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
공시 • Jan 21Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million.Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million on January 20, 2026. A cash consideration valued at €3.2 per share will be paid by Smart Capital S.p.A. Following the transaction, which took place outside the market, Smart Capital will hold 799,500 shares, thus increasing its stake from 5.00% to 12.01% of Arterra's share capital. Smart Capital S.p.A. (BIT:SMCAP) completed the acquisition of an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) on January 20, 2026.
New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.8m market cap, or US$24.2m).
Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €3.32, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total returns to shareholders of 114% over the past three years.
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (217% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€17.0m market cap, or US$19.8m).
New Risk • May 22New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 289% Dividend yield: 5.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (289% cash payout ratio). Market cap is less than US$100m (€15.6m market cap, or US$17.6m).
Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.6m revenue, or US$4.2m). Market cap is less than US$100m (€14.9m market cap, or US$17.0m).
분석 기사 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...
Buy Or Sell Opportunity • Apr 07Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €2.16. The fair value is estimated to be €1.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
공시 • Apr 07Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Location: via benedetto brin n 69 Italy
분석 기사 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...
Declared Dividend • Mar 31Dividend increased to €0.13Dividend of €0.13 is 30% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 6.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 31% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.
공시 • Mar 30Arterra Bioscience S.p.A. announces Annual dividend, payable on May 07, 2025Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1300 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.
Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.
Upcoming Dividend • Apr 29Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Trailing yield: 5.2%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.8%).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (€13.0m market cap, or US$13.8m).
분석 기사 • Feb 13Arterra Bioscience S.p.A.'s (BIT:ARBS) P/E Is On The MarkThere wouldn't be many who think Arterra Bioscience S.p.A.'s ( BIT:ARBS ) price-to-earnings (or "P/E") ratio of 12.6x...
Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.64, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 44% over the past three years.
Buying Opportunity • Sep 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €2.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
분석 기사 • Aug 03A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ARBS)Key Insights The projected fair value for Arterra Bioscience is €1.90 based on 2 Stage Free Cash Flow to Equity Arterra...
Upcoming Dividend • May 01Upcoming dividend of €0.10 per share at 4.0% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 4.0%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.4%).
분석 기사 • Jan 09A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ABS)Key Insights Arterra Bioscience's estimated fair value is €2.3 based on 2 Stage Free Cash Flow to Equity Current share...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Counselor Lucio Annunziato was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €2.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past year.
Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €2.21m (up 40% from 1H 2020). Net income: €390.6k (up 13% from 1H 2020). Profit margin: 18% (down from 22% in 1H 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 13Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €4.17m (up 19% from FY 2019). Net income: €1.11m (up 29% from FY 2019). Profit margin: 27% (up from 24% in FY 2019). The increase in margin was driven by higher revenue.
분석 기사 • May 27Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 23% share price gain to €4.08, the stock trades at a trailing P/E ratio of 46.8x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to €3.41, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total return to shareholders over the past year is a loss of 7.8%.
Is New 90 Day High Low • Jan 08New 90-day high: €3.41The company is up 15% from its price of €2.96 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €2.80The company is down 2.0% from its price of €2.87 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.